3D Global Biotech Inc. (TPEX:6808)
37.60
+0.60 (1.62%)
Aug 17, 2026, 1:43 PM CST
3D Global Biotech Revenue
3D Global Biotech had revenue of 103.89M TWD in the half year ending December 31, 2025, with 804.58% growth. This brings the company's revenue in the last twelve months to 159.19M, down -51.00% year-over-year. In the year 2025, 3D Global Biotech had annual revenue of 206.74M, down -22.19%.
Revenue (ttm)
159.19M
Revenue Growth
-51.00%
P/S Ratio
17.89
Revenue / Employee
n/a
Employees
43
Market Cap
2.85B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 206.74M | -58.95M | -22.19% |
| Dec 31, 2024 | 265.69M | 245.05M | 1,187.68% |
| Dec 31, 2023 | 20.63M | 6.99M | 51.24% |
| Dec 31, 2022 | 13.64M | 2.57M | 23.19% |
| Dec 31, 2021 | 11.08M | -2.19M | -16.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apex Biotechnology | 1.87B |
| SYN-TECH Chem. & Pharm. | 1.27B |
| Chunghwa Chemical Synthesis & Biotech | 934.29M |
| Sagittarius Life Science | 392.26M |
| BioGend Therapeutics | 236.58M |
| Shine-On BioMedical | 50.62M |
| Intech Biopharm | 48.55M |
| GlycoNex Incorporation | 36.35M |